Introduction
We actively develop cell therapies for various indications, aiming to provide more treatment options for patients worldwide and satisfy the unmet medical needs.
The preclinical study of GXIPC1®, used for the treatment of diabetes, has demonstrated its ability to effectively improve diabetic conditions by regulating blood glucose levels, maintaining islet cell number, and preserving islet morphology. This research results have been granted patent.
In 2019, GXIPC1® initiated a Phase I clinical trial at the Vinmec Research Institute of Stem Cell and Gene Technology (VIRISG). The Phase I clinical trial has now been completed. This represents an unprecedented case in Taiwan involving the cross-border delivery of prepared stem cells for the treatment of diabetes.
Features / strengths
．Allogeneic stem cell therapy
．No waiting time required (off-the-shelf)
．Cell source supported by U.S. FDA DMF compliance
．GXIPC1® is the first human clinical trial in Taiwan to deliver qualified allogeneic stem cells overseas for the conduct of a clinical study
．GXIPC1® has been approved by the Ministry of Health (MOH), the competent authority, for clinical trial completion in Vietnam
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Type 1 Diabetes
Administration
Intravenous injection
Product Status
Phase I (NCT05308836)
Supporting document
